Soleno Therapeutics (SLNO) Common Equity (2013 - 2026)

Soleno Therapeutics (SLNO) has 14 years of Common Equity data on file, last reported at $495.8 million in Q1 2026.

• On a quarterly basis, Common Equity rose 113.47% year-over-year to $495.8 million in Q1 2026; TTM through Mar 2026 was $495.8 million, a 113.47% increase from a year earlier, with the FY2025 full-year figure at $450.1 million, up 83.64% from the prior year.
• Common Equity for Q1 2026 stood at $495.8 million, up from $450.1 million in the prior quarter.
• Over the last five years, Common Equity for SLNO reached as high as $495.8 million in Q1 2026 and fell as low as $2.6 million in Q1 2023.
• Historically, Common Equity has averaged $183.2 million across 5 years, with a median of $157.5 million in 2023.
• Across the five-year window, Common Equity sank 90.03% in 2023 and surged 5333.35% in 2024, its largest moves.
• Year by year, Common Equity stood at $10.3 million in 2022, then surged by 1422.1% to $157.5 million in 2023, then jumped by 55.62% to $245.1 million in 2024, then jumped by 83.64% to $450.1 million in 2025, then climbed by 10.15% to $495.8 million in 2026.
• Per Business Quant data, the three most recent Common Equity figures were $495.8 million in Q1 2026, $450.1 million in Q4 2025, and $494.8 million in Q3 2025.